Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
Avidity Biosciences Inc (NASDAQ: RNA) closed the day trading at $45.78 down -1.10% from the previous closing price of $46.29. In other words, the price has decreased by -$1.10 from its previous closing price. On the day, 3.11 million shares were traded. RNA stock price reached its highest trading level at $46.0 during the session, while it also had its lowest trading level at $43.5.
Ratios:
For a better understanding of RNA, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 9.26 and its Current Ratio is at 9.26. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
On June 24, 2025, Bernstein started tracking the stock assigning a Outperform rating and target price of $50.
On June 17, 2025, Wolfe Research started tracking the stock assigning a Outperform rating and target price of $55.Wolfe Research initiated its Outperform rating on June 17, 2025, with a $55 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 06 ’25 when Mosbrooker Eric sold 130,807 shares for $44.06 per share. The transaction valued at 5,763,697 led to the insider holds 55,000 shares of the business.
WILSON TROY EDWARD sold 65,554 shares of RNA for $2,949,930 on Aug 06 ’25. The Director now owns 17,776 shares after completing the transaction at $45.00 per share. On Aug 06 ’25, another insider, WILSON TROY EDWARD, who serves as the Director of the company, sold 29,500 shares for $45.00 each. As a result, the insider received 1,327,500 and left with 69,425 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RNA now has a Market Capitalization of 5889734144 and an Enterprise Value of 4711740928. For the stock, the TTM Price-to-Sale (P/S) ratio is 548.90 while its Price-to-Book (P/B) ratio in mrq is 4.64. Its current Enterprise Value per Revenue stands at 439.159 whereas that against EBITDA is -9.083.
Stock Price History:
The Beta on a monthly basis for RNA is 0.97, which has changed by 0.01755941 over the last 52 weeks, in comparison to a change of 0.17279088 over the same period for the S&P500. Over the past 52 weeks, RNA has reached a high of $56.00, while it has fallen to a 52-week low of $21.51. The 50-Day Moving Average of the stock is 36.20%, while the 200-Day Moving Average is calculated to be 36.52%.
Shares Statistics:
Over the past 3-months, RNA traded about 2.22M shares per day on average, while over the past 10 days, RNA traded about 4794340 shares per day. A total of 120.78M shares are outstanding, with a floating share count of 117.11M. Insiders hold about 8.97% of the company’s shares, while institutions hold 101.38% stake in the company. Shares short for RNA as of 1752537600 were 16259911 with a Short Ratio of 7.32, compared to 1749772800 on 16344285. Therefore, it implies a Short% of Shares Outstanding of 16259911 and a Short% of Float of 13.62.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 15.0 analysts currently analyzing and rating the stock of Avidity Biosciences Inc (RNA).The consensus estimate for the next quarter is -$1.22, with high estimates of -$0.61 and low estimates of -$2.36.
Analysts are recommending an EPS of between -$3.33 and -$6.26 for the fiscal current year, implying an average EPS of -$4.39. EPS for the following year is -$4.79, with 17.0 analysts recommending between -$2.97 and -$7.31.
Revenue Estimates
A total of 13 analysts have provided revenue estimates for RNA’s current fiscal year. The highest revenue estimate was $13.14M, while the lowest revenue estimate was $5M, resulting in an average revenue estimate of $9.9M. In the same quarter a year ago, actual revenue was $10.9M
